



Europäisches Patentamt
European Patent Office
Office européen des brevets

⑪ Publication number:

0 138 222
A2

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 84112453.0

⑮ Int. Cl. 4: **C 12 P 21/00, C 12 N 15/00,**
C 12 N 5/00, C 07 K 3/18,
G 01 N 33/577
// (C12P21/00, C12R1:91)

⑭ Date of filing: 18.10.84

⑯ Priority: 18.10.83 GB 8327860

⑯ Applicant: Fujisawa Pharmaceutical Co., Ltd., 3,
Doshomachi 4-chome Higashi-ku, Osaka-shi,
Osaka 541 (JP)

⑰ Date of publication of application: 24.04.85
Bulletin 85/17

⑰ Inventor: Yamashita, Tatsuo, No. 3-10-2 Akibadai
Nishi-ku, Kobe-shi 657-02 (JP)
Inventor: Terada, Masafumi,
Daini-Tamagawa-Co-op 306 No.1-17-8 Iwatacho,
Higashiosaka-shi 578 (JP)
Inventor: Suzuki, Koji, Torii-utaku
No.3-11 No. 191-2 Toriicho, Tsu-shi 514 (JP)

⑲ Designated Contracting States: AT BE CH DE FR GB IT
LI NL SE

⑲ Representative: Türk, Dietmar, Dr. rer. nat. et al, Redies,
Redies, Türk & Güle Patentanwälte Brücknerstrasse 20,
D-4000 Düsseldorf 13 (DE)

⑳ Monoclonal anti-protein C antibody, its preparation and use thereof.

㉑ The invention relates to a monoclonal anti-protein C antibody produced by a hybridoma cell line and a hybridoma cell line secreting a monoclonal anti-protein C antibody. The invention further relates to an immunoabsorption purification process for the purification of protein C using monoclonal anti-protein C antibody as an immunoabsorbent and an enzyme-linked immunosorbent assay for the measurement of protein C.

EP 0 138 222 A2

5

10

15

MONOCLONAL ANTI-PROTEIN C ANTIBODY,
ITS PREPARATION AND USE THEREOF

This invention relates to a new monoclonal antibody produced by a hybridoma cell line.

20

More particularly, it relates to a new monoclonal protein C antibody produced by a hybridoma cell line, to a process for its preparation by a hybridoma cell line, to a hybridoma cell line secreting said antibody, to a process for purifying protein C using said antibody, to a enzyme-linked immunosorbent assay (hereinafter referred to ELISA) of protein C and radioimmunoassay (hereinafter referred to RIA) of protein C.

30

The monoclonal anti-protein C antibody of this invention can be prepared from cell culture of a mammalian hybridoma cell line produced by fusing a mammalian spleen cell and a mammalian myeloma cell in which the spleen cell is taken from the mammal immunized with protein C originated in mammal.

Fusion between a spleen cell and a myeloma cell is achieved by bringing them into contact in the presence of a fusion promoter (e.g. polyethyleneglycol). A small percentage of spleen cells and myeloma cells are fused to 5 produce hybridoma. Further, thus obtained hybridomas secrete various antibodies according to a variety of fused spleen cells. But, it is possible to isolate a hybridoma secreting desired antibody from thus obtained hybridomas by cloning.

10

Thus obtained and cloned hybridoma can be grown in a nutrient medium or in a peritoneal cavity of a mammal, and the produced antibody can be purified from culture supernatant, or ascitic fluid or serum of the mammal in a 15 conventional manner which are generally employed in the isolation and purification of protein from natural or artificial sources. As such a manner, there are exemplified, an isolation and purification method such as centrifugation, dialysis, precipitation with ammonium 20 sulfate, column chromatography using DEAE-cellulose, gel filtration, affinity column chromatography, lyophilization, and the like.

25

The advantage of this technique is that it provides a source of specific anti-protein C antibody directed against only a certain determinant and uncontaminated by antibodies raised by an antigenic impurities contained in the protein C preparation used. Another advantage of the technique is that substantial quantities of desired 30 anti-protein C antibody may easily be provided.

35

Thus obtained monoclonal anti-protein C antibody of this invention have a binding ability to protein C, and is adoptable as an immunoabsorbent in an immunoabsorption purification process for protein C. More particularly, a

monoclonal anti-protein C antibody of this invention can be bound to polysaccharide by reacting it with an activated polysaccharide (e.g. CNBr-activated Sepharose 4B (made by Pharmacia Fine Chemicals AB) in a 5 conventional manner.

The invention is described by the following experimental details which are given by way of example, not of limitation.

10

Example 1

Preparation of a monoclonal anti-human protein C antibody

15

(i) Preparation of immunized spleen cells

Protein C was purified from human plasma, showing single band electrophoretically. Thirty μ g of the protein 20 C solution was administered to each of 6 female BALB/c mice by intraperitoneal injection together with 100 μ l of diphtheria and tetanus toxoids and pertussis vaccine (made by the Institute of Microbiology of Osaka University; 2×10^{10} Bordetella pertussis are included in 25 1 ml). In Experiment 1, 14 days later, additional 30 μ g of the protein C in saline was administered intraperitoneally to each of 3 mice. After 15 days of the second administration, the same amounts of protein C in saline was administered intravenously to the mice. In 30 Experiment 2, 30 μ g of the protein C was administered intraperitoneally to each of the remained 3 mice with the same toxoids and vaccine after 14 days of first administration. After 30 days of second administration, 30 μ g of protein C in saline was administered 35 intravenously to the mice. After 4 days of the last

administration, 2 mice in Experiment 1 (1 mouse died) and 3 mice in Experiment 2 were sacrificed, and their spleens were taken to use for the cell fusion.

5 (ii) Production of hybridoma

10 The spleen cells prepared by teasing spleens with forceps were fused with mouse myeloma cells P3 X63 Ag8 U1 by the method of Köhler and Milstein (c.f. *Nature* , 256, 495-497 (1975)). The myeloma cells were provided by Dr. T. Watanabe, Saga Medical School, Saga-ken, Japan.

15 Namely, the spleen cells were suspended in Dulbecco's modified Eagle's minimum essential medium (hereinafter referred to D-MEM). The erythrocytes in the suspension were destroyed by treating with a mixture of 0.83% ammonium chloride solution (9 volume) and 0.17 M tris(hydroxymethyl)aminomethane-hydrochloric acid buffer solution (pH 7.65, 1 volume) at 4°C for 5 minutes and removed off by centrifugation. The mouse myeloma cells 20 which were cultured in D-MEM supplemented with 15% fetal bovine serum and spleen cells were washed several times with D-MEM.

25 To the suspension of the mouse myeloma cells (4×10^7 cells) was added the suspension of the spleen cells (2×10^8 cells). The mixture was well mixed in 50 ml plastic tube (Corning 50 ml centrifuge tube, made by Corning Glass Works). The medium was removed off by centrifugation. The cells were warmed in a water bath to 37°C. To the cells was gradually added 45% 30 polyethyleneglycol (made by Sigma; average molecular weight was 4,000) solution (1 ml) in the course of one minute, while shaking. The mixture was allowed to stand at room temperature for 7 minutes. The cell fusion reaction was stopped by adding 15 ml of D-MEM drop by drop to the reaction mixture in the course of 5 minutes.

After a large volume of D-MEM was added to the mixture, the mixture was centrifuged to remove supernatant. To the residue was added complete medium comprising D-MEM supplemented with 15% fetal bovine serum (made by 5 Centaurus, Lot 757), 2 mM glutamine, 2×10^{-5} M 2-mercaptoethanol, 100 μ g/ml streptomycin sulfate, 100 U/ml penicillin G, 80 μ g/ml gentamicin sulfate and 0.25 μ g/ml Fungizone (Amphotericin B, GIBCO Lab.) (hereinafter referred to CM). After the mixture was slightly mixed, 10 1 ml of the resultant fused cell suspensions was distributed in each well of ten 24-well plates (Nunc) at a ratio of 1×10^6 spleen cells per well. One day after the incubation at 37°C in 5% carbon dioxide atmosphere, 15 1 ml of CM containing aminopterine (4×10^{-7} M), thymidine (1.6×10^{-5} M) and hypoxanthine (1×10^{-4} M) (HAT medium) was added to each well. After one day, a half volume of the medium in each well was removed by suction and the HAT medium was added to each well every second or third day.

20 Fourteen days after the cell fusion, growth of hybrid cells was observed in almost all wells.

(iii) Assay of anti-protein C antibody

25 To each well of 96-well plates (made by Cooke, M-174, cup U rigid immulon) was added 100 μ l of 50 μ g/ml protein C solution or bovine serum albumin solution, and the plates were incubated at 4°C overnight for the well to be coated with protein C. Then, a solution of bovine 30 serum albumin (20 μ l/ml) was added to block well completely. To each well 100 μ l of the above-obtained supernatant of the hybridoma culture was added and was incubated at 37°C for 90 minutes. After washed with phosphate buffered saline (hereinafter referred to PBS) 35 3 times, 100 μ l of affinity chromatography-purified,

¹²⁵I-labelled goat anti-mouse IgG F(ab')₂ solution (10,000 cpm, specific activity 1 Ci/ μ g IgG) was added thereto and was incubated at 37°C 1 hour. The radioactivity of each well was determined by a gamma 5 scintillation counter. Cultures showing binding activity to protein C, not to bovine serum albumin, were selected as culture producing anti-human protein C antibody. Anti-protein C activity was detected in 1 culture of 29 cultures assayed in Experiment 1 and 51 cultures of 226 10 cultures assayed in Experiment 2.

(iv) Cloning of a hybridoma producing anti-human protein C antibody

15 Twenty hybridoma cell cultures which showed high binding activity to protein C were cloned by limiting dilution in 96-well flat-bottomed micro test plate (made by NUNC) using BALB/c mouse thymocytes as feeder layer (5 $\times 10^6$ cells/ml).

20 (v) Purification of monoclonal anti-human protein C antibody

25 The above-obtained hybridoma was transplanted intraperitoneally to a BALB/c mouse which had been administered with tetramethylpentadecane 1 week earlier. After about 1 week, ascites was taken from peritoneal cavity of the mouse, from which monoclonal anti-protein C antibody was isolated by 50% saturated ammonium sulfate 30 solution.

35 Namely, after removing hybridoma cells from the ascitic fluid by centrifugation, to the supernatant was gradually added ammonium sulfate at a final concentration of 50% saturation while stirring. The mixture was stirred under ice-cooling for 30 minutes and allowed to stand for

60 minutes. After centrifuging the mixture, resultant residue was dissolved in a small volume of 20 mM tris(hydroxymethyl)aminoethane-hydrochloric acid-20 mM NaCl buffer (pH 7.9), was dialyzed against the same 5 buffer and was subjected to a column chromatography on DEAE-cellulose (DE52, made by Whatman Chemical Separation Ltd.) equilibrated with the same buffer. Elution of the monoclonal antibody was carried out with a linear gradient of 20 mM tris(hydroxymethyl)aminomethane- 10 hydrochloric acid-20 mM NaCl buffer (pH 7.9) and 40 mM tris(hydroxymethyl)aminomethane-hydrochloric acid-0.5 M NaCl buffer (pH 7.9). Thus obtained eluate was used as an immunoadsorbent in a purification process for protein C, particulars of which are described in Example 2 (ii), and 15 as antibodies of ELISA for human protein C, particulars of which are described in Example 2 (iii).

(vi) Measurement of molecular weight of antibody:

20 Molecular weight of antibody was determined by SDS-polyacrylamide gel electrophoresis.

(1) Under non-reducing condition:

25 (a) Monoclonal anti-human protein C antibody 1-18-10 produced by Mouse hybridoma PC 1-18-10:

194,000

30 (b) Monoclonal anti-human protein C antibody 3-15-7 produced by Mouse hybridoma PC 3-15-7:

202,000

35 (c) Monoclonal anti-human protein C antibody 2-41-3

produced by Mouse hybridoma PC 2-41-3:

192,000

5 (d) Monoclonal anti-human protein C antibody 2-105-6
produced by Mouse hybridoma PC 2-105-6:

192,000

10 (e) Monoclonal anti-human protein C antibody 3-54-5
produced by Mouse hybridoma PC 3-54-5:

185,000

15 (2) Under reduced condition:

Monoclonal anti-human protein C antibody thus
obtained was reduced by 2-mercaptoethanol. In this
condition monoclonal anti-human protein C antibody was
20 dissociated to 2 molecules.

(a) Monoclonal anti-human protein C antibody 1-18-10
produced by Mouse hybridoma PC 1-18-10:

25 26,000 and 45,000

(b) Monoclonal anti-human protein C antibody 3-15-7
produced by Mouse hybridoma PC 3-15-7:

30 29,000 and 46,000

(c) Monoclonal anti-human protein C antibody 2-41-3
produced by Mouse hybridoma PC 2-41-3:

35 27,000 and 50,000

0138222

(d) Monoclonal anti-human protein C antibody 2-105-6
produced by Mouse hybridoma PC 2-105-6:

26,000 and 46,000

5

(e) Monoclonal anti-human protein C antibody 3-54-5
produced by Mouse hybridoma PC 3-54-5:

28,000 and 46,000

10

(vii) Identification of immunoglobulin class of an
antibody

15 Culture supernatant were added with equal volume of
saturated ammonium sulfate solution and allowed to stand
for 1 hour on ice. The precipitates obtained by
centrifugation were dissolved in one tenth volume of PBS.

20 Identification of immunoglobulin of antibodies thus
obtained was conducted by the method of Ouchterlony's
double immunodiffusion method. Polyclonal goat antibodies
(made by Miles) were used to characterize each subclass
of monoclonal antibodies.

25 Thus obtained monoclonal anti-protein C antibodies
are as follows.

(1) Monoclonal anti-human protein C antibody 1-18-10
produced by Mouse hybridoma PC 1-18-10:

30 (a) Subclass: IgG₁

(2) Monoclonal anti-human protein C antibody 2-22-1
produced by Mouse hybridoma PC 2-22-1:

35 (a) Subclass: IgG₁

(3) Monoclonal anti-human protein C antibody 2-27-4
produced by Mouse hybridoma PC 2-27-4:

(a) Subclass: IgG_{2a}

5

(4) Monoclonal anti-human protein C antibody 2-41-3
produced by Mouse hybridoma PC 2-41-3:

(a) Subclass: IgG_{2b}

10

(5) Monoclonal anti-human protein C antibody 2-45-9
produced by Mouse hybridoma PC 2-45-9:

(a) Subclass: IgG₁

15

(6) Monoclonal anti-human protein C antibody 2-47-8
produced by Mouse hybridoma PC 2-47-8:

(a) Subclass: IgG₁

20

(7) Monoclonal anti-human protein C antibody 2-95-2
produced by Mouse hybridoma PC 2-95-2:

(a) Subclass: IgG₁

25

(8) Monoclonal anti-human protein C antibody 2-97-10
produced by Mouse hybridoma PC 2-97-10:

(a) Subclass: IgG₁

30

(9) Monoclonal anti-human protein C antibody
2-101-17 by Mouse hybridoma PC 2-101-17

(a) Subclass: IgG₁

35

(10) Monoclonal anti-human protein C antibody
2-105-6 produced by Mouse hybridoma PC 2-105-6:

(a) Subclass: IgG₁

5

(11) Monoclonal anti-human protein C antibody
2-115-1 produced by Mouse hybridoma PC 2-115-1:

(a) Subclass: IgG₁

10

(12) Monoclonal anti-human protein C antibody 3-15-7
produced by Mouse hybridoma PC 3-15-7:

(a) Subclass: IgG₁

15

(13) Monoclonal anti-human protein C antibody 3-54-5
produced by Mouse hybridoma PC 3-54-5:

(a) Subclass: IgG_{2a}

20

Example 2

Application of a monoclonal anti-human protein C
antibody to a process for the purification of protein C

25

(i) Coupling of a monoclonal anti-protein C antibody
to CNBr-activated Sepharose 4B (made by Pharmacia Fine
Chemicals AB)

30

CNBr-activated Sepharose 4B (0.7 g) was washed with
1 mM hydrogen chloride and coupling buffer containing 0.1
M sodium bicarbonate (pH 8.3) and 0.5 M sodium chloride,
successively, to prepare a solution of CNBr-activated
Sephrose 4B in coupling buffer (3 ml). To 1 ml of the
35 solution was added 3 ml of coupling buffer solution of

monoclonal anti-human protein C antibody 3-15-7 (3.7 mg, protein) prepared in Example 1, which had been prepared by dialysis. The resultant mixture was allowed to shake at room temperature for 2 hours. After washing the 5 mixture by 5 to 7 ml of PBS on G3 glass filter, 1 M ethanalamine-HCl (4 ml, pH 8.0) was added thereto and was allowed to shake at a room temperature for 2 hours to block remaining active site. After blocking, the resultant antibody-coupled Sepharose 4B solution was 10 washed with a solution of 0.1 M acetate buffer (pH 4.0) containing 0.5 M sodium chloride and coupling buffer mentioned above, successively (three times) and was equilibrated with 25 mM sodium phosphate buffer (pH 7.4) containing 0.5 sodium chloride after washing 20 ml of PBS 15 containing 0.1% bovine serum albumin. Thus obtained CNBr-activated Sepharose 4B coupled monoclonal anti-protein C antibody (hereinafter referred to antibody-coupled Sepharose 4B, specifically Column 3-15-7, was used for affinity column chromatography.

20

(ii) Adsorption and elution of protein C to antibody-coupled Sepharose 4B

Antibody-coupled Sepharose 4B (0.5 ml) was packed to 25 a column which was equilibrated with 25 mM sodium phosphate buffer (pH 7.4) containing 0.5 M sodium chloride. Crude human protein C applied for affinity chromatography was prepared as followed. To 25 ml of human plasma from blood of 5 healthy men was added 2 ml 30 of 1 M BaCl_2 in the presence of benzamidine. Precipitate was collected by centrifugation, following washing with 0.15 M sodium chloride solution containing 5 mM benzamidine. The precipitate is dissolved in 0.25 M EDTA 35 and 5 mM benzamidine solution. The protein solution obtained by centrifugation is dialyzed against PBS. The

solution containing crude human protein C was loaded on the column, washed with PBS, eluted with 3M potassium thiocyanate solution. Protein C was assayed by ELISA described later.

5 Protein C activity was not detected in passed-through fractions from column, so almost all parts of protein C was thought to have bound to the column. Yields of protein C eluted was 73.1% of the charged protein C, on the other hand, only 1% of protein C and a large amounts
10 of contaminated protein passed through.

The results are shown in the following Table 1.

(continued to the next page)

15

20

25

30

35

Table 1 Affinity chromatography of crude protein C using Column 3-15-7

5		Protein	Protein C	Yield	Purification
		μg	μg	%	factor, fold
Charged crude					
10	protein C	804	6.24	100	1.0
	solution				
	passed-through	781	0.064	1	0.0
	fraction				
15					
	3M KSCN eluate	48.5	4.56	73.1	12.1

20 (iii) Enzyme-linked immunosorbent assay for human protein C using anti-human protein C monoclonal antibody:

25 Anti-human protein C monoclonal antibody was purified as described above. Conjugation of horse radish peroxidase (hereinafter referred to POD) (type IV, made by Sigma) to monoclonal antibody was performed as described by Nakane and Kawaoi (Nakane, R. K. and A. Kawaoi, J. Histochem. Cytochem. 27, 1148(1974)). One step sandwich ELISA was performed as follows. One hundred μ l

30 of POD-conjugated anti-human protein C monoclonal antibody (A) in PBS containing 0.5% bovine serum albumin and 0.05% Tween 20 (polyoxyethylene sorbitan monolaurate, made by Kao Atlas Co., Ltd.) and 100 μ l of sample or purified protein C (standard) were added to each well of

35 96-well plate (made by Sumitomo Bakelite) precoated with

10 µg/ml of anti-human protein C monoclonal antibody (B) at room temperature for 1 hour, followed by washing three times with PBS containing 0.1% bovine serum albumin and 0.05% Tween 20. After incubation at room temperature for 5 1 hour, the wells were washed in the same manner, then 200 µl of substrate solution (2.5 mg/ml 0-phenylenediamine dihydrochloride and 0.018% H₂O₂ in 0.1M citrate-phosphate buffer, pH 5.4) was added. After 10 30 minutes the reaction was stopped by the addition of 50 µl of 20% sulfonic acid. The absorbance was read on a MR miro-ELISA microreader (made by Dynatech Inc.) at wavelength of 490 nm.

The results are shown in the following Table 2.

15

(continued to the next page)

20

25

30

35

Table 2 Combination of monoclonal antibodies applicable for ELISA of human protein C

		(A) : enzyme-conjugated monoclonal antibody			
		2-101-17	2-105-6	3-15-7	3-54-5
(B) Monoclonal antibody for coating	1-18-10	1	1	1	3
	2-41-3	2	1	2	1
	2-27-4	2	1	2	1
	2-101-17	3	1	3	1
	2-115-1	3	1	3	1
	2-47-8	3	1	3	1
	2-45-9	1	1	1	1
	2-105-6	1	3	1	1
	3-15-7	3	1	3	1
	3-54-5	1	1	1	3

1: applicable

2: poorly applicable

3: not applicable

This results show that the use of same antibody for enzyme-conjugation and coating is impossible because of the competition on the certain determinant. This means that applicable combination of antibodies comprise 5 antibodies directed to different determinant. These antibodies are classified as follows.

Group A: 1-18-10, 3-54-5
Group B: 2-105-6
10 Group C: 3-15-7, 2-101-17, 2-115-1, 2-47-8
Group D: 2-27-4, 2-41-3
Group E: 2-45-9

15 Combination of monoclonal antibodies for best sensitive assay is 2-105-6 for coating and 3-54-5 for enzyme-conjugation. ELISA with this combination was able to detect 1-100 ng/ ml of purified protein C.

20 Further, ELISA with this combination was possible to detect protein C in human plasma after dilution of 80 to 2,560 fold. The concentration of protein C in human plasma determined in this ELISA was 4.96 μ g/ml.

25 (iv) Inhibition of activated protein C activity by monoclonal antibody

Protein C is activated by thrombin to protein Ca which acts as a serine protease to activated Factor V or synthetic substrate. Protein C activated by the reaction with thrombin-coupled Sepharose 4B at 37°C for 1 hour was 30 incubated with 100 μ g/ml of monoclonal antibody at 37°C overnight. After the incubation, synthetic fluorescent substrate (t-butyloxycarboxy-Leu-Ser-Thr-Arg-4-methyl-coumaryl-7-amide) was added to the incubation mixture and the mixture was incubated at room temperature for 30 35 minutes. The measurements of fluorescence emitted by

hydrolytic activity of protein Ca was carried out with excitation at 380 nm and emission at 460 nm.

Antibodies 1-18-10 and 3-54-5 inhibited the protein Ca activity at the ratio of 78.7% and 79.4%. Antibodies 5 2-27-4, 2-41-3, 2-45-9, 2-47-8, 2-101-17, 2-105-6 and 2-115-1 showed no inhibition.

(v) Inhibition of the effect of activated protein C to Factor Va by monoclonal antibody

10

The effect of monoclonal antibody to the inactivation of Factor Va (activated Factor V) by protein C was examined by measuring the change in prothrombinase activity of Factor Va using fluorescent synthetic substrate (t-butyloxycarboxy-Val-Pro-Arg-4-methyl-coumaryl-7-amide) in the presence of activated Factor X, Calcium ion and phospholipid.

Antibody 3-54-5, 1-18-10, 2-101-17, 2-105-6 and 2-115-1 inhibited the inactivation of Factor Va by 20 protein C.

(vi) Inhibition of the activation of protein C by monoclonal antibody

25 Protein C was incubated with 500 µg/ml of monoclonal antibody at 37°C overnight, then thrombin-coupled Sepharose 4B was added and the mixture was incubated at 37°C for 1 hour with shaking. After centrifugation of the mixture, fluorescent synthetic substrate as described 30 above was added to the supernatant and the mixture was incubated at room temperature for 30 minutes. The measurement of fluorescence was carried out in the same manner.

Antibody 2-45-9, 1-18-10 and 3-54-5 inhibited the 35 reaction. From the results of example 2 (iv) and this

example, antibody 2-45-9 was thought to inhibit the effect of thrombin to the heavy chain of protein C.

5 (vii) Blocking of the inhibitory effect of protein C inhibitor on protein Ca by monoclonal antibody

30 μ l of protein Ca (2.0 μ g) and 20 μ l of monoclonal antibody (9.6 μ g) were incubated in 750 μ l of the buffer 10 consisting of 0.05 M Tris-HCl, pH 7.5, 0.1 M NaCl and 0.1% bovine serum albumin at 4° C overnight. Then, 200 μ l of protein C inhibitor (2.0 μ g) was added, and residual activity of protein Ca was measured using the synthetic fluorescent substrate (t-butyloxycarboxy-Leu-Ser-Thr- 15 Arg-4-methylcoumaryl-7-amide). When the protein Ca was treated with antibody 1-18-10, a half of the enzyme activity remained before addition of the inhibitor, however, this activity decreased very little even 50 minutes after addition of the inhibitor. Antibody 1-18-10 20 was thought to block the action of the protein C inhibitor on protein Ca.

25 (viii) Inhibition of the stimulatory effect of protein S on the protein Ca-catalyzed inactivation of coagulation factor Factor Va

The protein Ca-catalyzed inactivation of coagulation Factor Va is stimulated about fifteen times by another vitamin K-dependent protein S. Protein Ca was treated 30 beforehand with the monoclonal antibody at 4° C overnight. When the effect of protein Ca on the inactivation of Factor Va was examined by measuring the change in prothrombinase activity of Factor Va as described in Example 2 (v), the stimulatory effect of

protein S on the action of protein C_a was specifically inhibited 90% by antibody 2-115-1 and 60% by 2-101-17.

(ix) Antigenic determinant of monoclonal antibody

5

Antigenic determinant of monoclonal antibody on protein C was examined with immunoblotting system (Bio-Rad Lab.) using goat anti-mouse IgG as second antibody and autoradiography.

10 Antibody 1-18-10, 2-45-9, 2-105-6, 3-15-7 and 3-54-5 were found to bind to the heavy chain of protein C. Antibody 2-27-4, 2-41-3 2-95-2 and 2-115-1 were assumed to bind to the light chain. Antibody 2-47-8 and 2-97-10 were speculated to direct toward. The antigenic 15 determinant containing amino acids on both the light and heavy chains of protein C or toward a specific conformation of intact protein C.

20

25

30

35

What we claim is:

1. A monoclonal anti-protein C antibody produced by a hybridoma cell line.
- 5 2. A hybridoma cell line secreting a monoclonal anti-protein C antibody.
- 10 3. An immunoadsorption purification process for the purification of protein C using monoclonal anti-protein C antibody as an immunoabsorbent.
- 15 4. An enzyme-linked immunosorbent assay for the measurement of protein C.

20

25

30

35



Europäisches Patentamt

European Patent Office

Office européen des brevets

⑪ Publication number:

0 138 222

A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 84112453.0

⑮ Int. Cl³: C 12 P 21/00

⑭ Date of filing: 16.10.84

C 12 N 15/00, C 12 N 5/00
C 07 K 3/18, G 01 N 33/577
//(C12P21/00, C12R1:91)

⑯ Priority: 18.10.83 GB 8327860

⑰ Applicant: Fujisawa Pharmaceutical Co., Ltd.
3, Doshimachi 4-chome Higashi-ku
Osaka-shi, Osaka 541(JP)

⑱ Date of publication of application:
24.04.85 Bulletin 85/17

⑲ Inventor: Yamashita, Tatsuo
No. 3-10-2 Akibadai Nishi-ku
Kobe-shi 657-02(JP)

⑳ Date of deferred publication of search report: 04.11.87

⑳ Inventor: Terada, Masafumi
Daini-Tamagawa-Co-op 306 No.1-17-6 Hwatacho
Higashiosaka-shi 578(JP)

㉑ Designated Contracting States:
AT BE CH DE FR GB IT LI NL SE

㉑ Inventor: Suzuki, Koji
Torii-jutaku No.3-11 No. 191-2 Toriicho
Tsu-shi 514(JP)

㉒ Representative: Türk, Dietmar, Dr. rer. nat. et al.
Türk, Gille + Hrabal Patentanwälte Brückner Strasse 20
D-4000 Düsseldorf 13(DE)

㉓ Monoclonal anti-protein C antibody, its preparation and use thereof.

㉔ The invention relates to a monoclonal anti-protein C antibody produced by a hybridoma cell line and a hybridoma cell line secreting a monoclonal anti-protein C antibody. The invention further relates to an immunoabsorption purification process for the purification of protein C using monoclonal anti-protein C antibody as an immunoabsorbent and an enzyme-linked immunosorbent assay for the measurement of protein C.

EP 0 138 222 A3

EUROPEAN SEARCH REPORT

 0138222
Application number

EP 84 11 2453

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
E	WO-A-8 501 941 (NEW ENGLAND MEDICAL CENTER HOSPITALS) * Page 7, lines 28-32; page 8, lines 1-7,21-24; page 26, claim 2; page 27, claims 8,10 *	1-4	C 12 P 21/00 C 12 N 15/00 C 12 N 5/00 C 07 K 3/18 G 01 N 33/577
X,P	--- EP-A-0 118 256 (SCRIPPS CLINIC AND RESEARCH FOUNDATION) * Page 2, lines 29-34; page 3, lines 1-13,21-25 *	1-4	
X,P	--- CHEMICAL ABSTRACTS, vol. 101, no. 7, 13th August 1984, page 461, abstract no. 53016v, Columbus, Ohio, US; K. SUZUKI et al.: "Preparation of monoclonal antibodies to human protein C. Effects on activated protein C and its zymogen", & KETSUEKI TO MYAKKAN 1984, 15(2), 171-4 * Abstract *	1-4	
	-----		TECHNICAL FIELDS SEARCHED (Int. Cl.4)
			C 12 P A 61 K G 01 N
The present search report has been drawn up for all claims			
Place of search THE HAGUE	Date of completion of the search 10-08-1987	Examiner FERNANDEZ Y BRANAS E	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	& : member of the same patent family, corresponding document		